Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

P8828

Sigma-Aldrich

Pergolide mesylate salt

≥98%, solid

Synonym(s):

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

Sign Into View Organizational & Contract Pricing

Select a Size

All Photos(1)

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C19H26N2S · CH4O3S
CAS Number:
66104-23-2
Molecular Weight:
410.59
MDL number:
MFCD00153859
UNSPSC Code:
12352200
PubChem Substance ID:
24277927
NACRES:
NA.77

Assay

≥98%

form

solid

optical activity

[α]20/D −35°, c = 0.2 in pyridine(lit.)

color

white

solubility

ethanol: 2 mg/mL
DMSO: 5.2 mg/mL
H2O: insoluble

originator

Valeant

storage temp.

−20°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1

InChI key

UWCVGPLTGZWHGS-ZORIOUSZSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

Features and Benefits

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H300

Precautionary Statements

P264 - P301 + P310

Hazard Classifications

Acute Tox. 2 Oral

Storage Class Code

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

P8828-BULK:
P8828-100MG:
P8828-VAR:
P8828-25MG:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLBM6092V
SLBF6838V
070M2011V
070M2011
119K1638

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Richard P Allen et al.
Sleep medicine, 12(5), 431-439 (2011-04-16)
Assess the rate of augmentation as it occurs during standard long-term dopaminergic treatment of RLS, potential risk factors or predictors of augmentation, the relationship between treatment duration and augmentation, and the clinical impact of augmentation on subjects' health outcomes. Two
Marie Innerå et al.
Veterinary dermatology, 24(1), 212-217 (2013-01-22)
Pituitary pars intermedia dysfunction (PPID) in older equids is commonly recognized by a long hair coat that fails to shed. The aim of this study was to compare hair follicle stages in PPID-affected horses with excessively long hair coats with
P Barone et al.
Neurology, 53(3), 573-579 (1999-08-17)
To determine whether pergolide monotherapy provides symptomatic relief in early PD. Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 dopamine agonist, has been studied as
Alin Ciobica et al.
Journal of physiology and biochemistry, 68(1), 59-69 (2011-10-19)
One of the most widely used animal models of Parkinson's disease (PD) involves injecting 6-hydroxydopamine (6-OHDA) directly into the substantia nigra (SN). Some recent reports speculated that dopaminergic drugs may exert brain antioxidant activity, which could explain some of their
Nathan Silver et al.
Sleep medicine, 12(5), 440-444 (2011-01-18)
Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments. Currently, the most commonly
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service